OTCMKTS:WILYYDEMANT A S/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DEMANT A S/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.49 0.00 (0.00 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$15.49Now: $15.49▼$15.4950-Day Range$13.08MA: $14.18▼$15.4952-Week Range$11.17Now: $15.49▼$15.49VolumeN/AAverage Volume67 shsMarket Capitalization$7.46 billionP/E Ratio34.42Dividend YieldN/ABeta0.23 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesShort InterestSocial Media Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic instruments; and personal communication systems, such as headsets and solutions for the professional call center and office market, as well as consumer headsets for the gaming and mobile segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for DEMANT A S/ADR. Previous Next 1.9 Community Rank Outperform VotesDEMANT A S/ADR has received 181 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDEMANT A S/ADR has received 289 “underperform” votes. (Add your “underperform” vote.)Community SentimentDEMANT A S/ADR has received 61.49% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DEMANT A S/ADR and other stocks. Vote “Outperform” if you believe WILYY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe WILYY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDEMANT A S/ADR does not currently pay a dividend.Dividend GrowthDEMANT A S/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DEMANT A S/ADR insiders have not sold or bought any company stock. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for DEMANT A S/ADR are expected to grow by 54.76% in the coming year, from $0.42 to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DEMANT A S/ADR is 34.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.78.Price to Earnings Ratio vs. SectorThe P/E ratio of DEMANT A S/ADR is 34.42, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.78.Price to Book Value per Share RatioDEMANT A S/ADR has a P/B Ratio of 6.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.76 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:WILYY Previous SymbolNASDAQ:WILYY CUSIPN/A CIKN/A Webwww.demant.com Phone45-3917-7300Debt Debt-to-Equity Ratio0.33 Current Ratio0.78 Quick Ratio0.57Price-To-Earnings Trailing P/E Ratio34.42 Forward P/E Ratio36.88 P/E GrowthN/A Sales & Book Value Annual Sales$2.24 billion Price / Sales3.33 Cash Flow$0.45 per share Price / Cash Flow34.66 Book Value$2.34 per share Price / Book6.62Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15,837 Outstanding Shares481,380,000Market Cap$7.46 billion Next Earnings DateN/A OptionableNot Optionable $15.49 0.00 (0.00 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive WILYY News and Ratings via Email Sign-up to receive the latest news and ratings for WILYY and its competitors with MarketBeat's FREE daily newsletter. DEMANT A S/ADR (OTCMKTS:WILYY) Frequently Asked Questions How has DEMANT A S/ADR's stock been impacted by COVID-19 (Coronavirus)? DEMANT A S/ADR's stock was trading at $16.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, WILYY shares have decreased by 3.8% and is now trading at $15.49. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DEMANT A S/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DEMANT A S/ADR in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for DEMANT A S/ADR. Has DEMANT A S/ADR been receiving favorable news coverage? News stories about WILYY stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DEMANT A S/ADR earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about DEMANT A S/ADR. Are investors shorting DEMANT A S/ADR? DEMANT A S/ADR saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 400 shares, a decline of 20.0% from the December 15th total of 500 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 4.0 days. View DEMANT A S/ADR's Short Interest. Who are some of DEMANT A S/ADR's key competitors? Some companies that are related to DEMANT A S/ADR include Zimmer Biomet (ZBH), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), Wound Management Technologies (WNDM), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE) and ConforMIS (CFMS). View all competitors. Who are DEMANT A S/ADR's key executives? DEMANT A S/ADR's management team includes the following people: Mr. Søren Nielsen, CEO, Pres & Member of Exec. Board (Age 49)Mr. René Schneider, CFO & Member of Exec. Board (Age 46)Mr. Søren Bergholt Andersson, VP of Investor Relations (Age 42)Ms. Trine Kromann-Mikkelsen, VP of Corp. Communication & RelationsMr. Jes Olsen, Pres of Oticon Medical What is DEMANT A S/ADR's stock symbol? DEMANT A S/ADR trades on the OTCMKTS under the ticker symbol "WILYY." How do I buy shares of DEMANT A S/ADR? Shares of WILYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DEMANT A S/ADR's stock price today? One share of WILYY stock can currently be purchased for approximately $15.49. How big of a company is DEMANT A S/ADR? DEMANT A S/ADR has a market capitalization of $7.46 billion and generates $2.24 billion in revenue each year. The company earns $219.15 million in net income (profit) each year or $0.45 on an earnings per share basis. DEMANT A S/ADR employs 15,837 workers across the globe. What is DEMANT A S/ADR's official website? The official website for DEMANT A S/ADR is www.demant.com. How can I contact DEMANT A S/ADR? DEMANT A S/ADR's mailing address is Kongebakken 9, Smorum G7, 2765. The company can be reached via phone at 45-3917-7300 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
